The number of approved innovative drugs and medical devices in the first half of the year saw a significant year-on-year increase.

According to the National Medical Products Administration, in the first half of this year, China approved 43 innovative drugs and 45 innovative medical devices, an increase of 59% and 87% respectively compared to the same period last year. The dividends of reform policies are being transformed into industrial development momentum. Since last year, the National Medical Products Administration has conducted pilot reforms to optimize drug supplementary applications in 11 provincial level bureaus. The time limit for supplementary application reviews that require verification and testing has been shortened from 200 working days to 60 working days. At the same time, efforts are being made to complete the review and approval of key innovative drug clinical trials within 30 working days. In the first half of the year, 70 new children's medicines and 21 rare disease drugs were approved.